Journal
FRONTIERS IN NEUROSCIENCE
Volume 15, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fnins.2021.641047
Keywords
NMDA receptor; glutamate; schizophrenia; cognitive dysfunction; negative symptoms
Categories
Funding
- National Science Foundation of China [2016YFC1306900]
- National Natural Science Foundation of China [82072096]
Ask authors/readers for more resources
The NMDAR hypofunction hypothesis offers a new perspective for treating negative symptoms and cognitive dysfunction in schizophrenia, with drugs targeting this receptor showing promise in improving symptoms. However, unsatisfactory outcomes in clinical studies suggest further research is needed to effectively utilize this hypothesis.
Treatments for negative symptoms and cognitive dysfunction in schizophrenia remain issues that psychiatrists around the world are trying to solve. Their mechanisms may be associated with N-methyl-D-aspartate receptors (NMDARs). The NMDAR hypofunction hypothesis for schizophrenia was brought to the fore mainly based on the clinical effects of NMDAR antagonists and anti-NMDAR encephalitis pathology. Drugs targeted at augmenting NMDAR function in the brain seem to be promising in improving negative symptoms and cognitive dysfunction in patients with schizophrenia. In this review, we list NMDAR-targeted drugs and report on related clinical studies. We then summarize their effects on negative symptoms and cognitive dysfunction and analyze the unsatisfactory outcomes of these clinical studies according to the improved glutamate hypothesis that has been revealed in animal models. We aimed to provide perspectives for scientists who sought therapeutic strategies for negative symptoms and cognitive dysfunction in schizophrenia based on the NMDAR hypofunction hypothesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available